← Leaderboards
Jennifer Bacik McCormack
The Emmes Company, Llc
$1,938,740
Attributed
$1,938,740
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $474.7K · FY2018–22$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,938,740 · 1
By mechanism
UG1$1,938,740 · 1
Top collaborators
No co-investigators on record.
Most similar at The Emmes Company, Llc
Same institution · by research overlap
- Keri Hammel$53,700,408
- Darby Thompson$10,610,431
- Supriya Menezes$25,277,032
- Keri, Hammel$11,064,901
Others in their field
Other Emerging Leaders on “Stem Cell Therapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Bronwen Shaw · Medical College Of Wisconsin$24,584,971
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- James Dale Berry · Brigham And Women'S Hospital$11,004,714
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$7,436,945
- Avnesh Sinh Thakor · Stanford University$7,297,208
Research focus
Stem Cell TherapyAdultAreaAutologousBlindnessBone CellBone MarrowCd34 GeneSiteAdherenceClinical TrialsCollaborationsConduct Clinical TrialsCross-Over StudiesData CollectionData Coordinating CenterData ManagementData ReportingDesignDouble-Blind MethodEnsureFundingHuman SubjectIntravitreal Injection
Grant awards (5)
Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$315,485
UG1 · FY2022 · EY · contact PI
Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$283,361
UG1 · FY2021 · EY · contact PI
Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$431,909
UG1 · FY2020 · EY · contact PI
Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$433,262
UG1 · FY2019 · EY · contact PI
Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion$474,723
UG1 · FY2018 · EY · contact PI